Patents by Inventor DANIELA BORNIGEN

DANIELA BORNIGEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for screening and identifying clinically aggressive prostate cancer
    Patent number: 11971411
    Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 30, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Curtis Huttenhower, Travis Gerke, Christopher Sweeney, Lorelei Mucci, Gwo-Sho Mary Lee, Daniela Bornigen, Xiaodong Wang, Svitlana Tyekucheva, Kristina Jordahl
  • COMPOSITIONS AND METHODS FOR SCREENING AND IDENTIFYING CLINICALLY AGGRESSIVE PROSTATE CANCER
    Publication number: 20200041515
    Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
    Type: Application
    Filed: January 20, 2017
    Publication date: February 6, 2020
    Inventors: CURTIS HUTTENHOWER, TRAVIS GERKE, CHRISTOPHER SWEENEY, LORELEI MUCCI, GWO-SHO MARY LEE, DANIELA BORNIGEN, XIAODONG WANG, SVITLANA TYEKUCHEVA, KRISTINA JORDAHL